Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.24.10621

High Expression of Forkhead Box Protein C2 is Related to Poor Prognosis in Human Gliomas  

Wang, Yao-Wu (Department of Neurosurgery, The Second Hospital of Hebei Medical University)
Yin, Chun-Li (Department of Neurosurgery, Tangshan Gongren Hospital)
Zhang, Hong-Yi (Department of Neurosurgery, Tangshan Gongren Hospital)
Hao, Jin-Min (Department of Neurosurgery, The Second Hospital of Hebei Medical University)
Yang, Yue-Ye (Department of Neurosurgery, Tangshan Gongren Hospital)
Liao, Heng (Department of Neurosurgery, Tangshan Gongren Hospital)
Jiao, Bao-Hua (Department of Neurosurgery, The Second Hospital of Hebei Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.24, 2015 , pp. 10621-10625 More about this Journal
Abstract
Background: Increasing evidence has indicated that high Forkhead box protein C2 (FOXC2) level is closely associated with the development, progression, and poor prognosis of a variety of tumors. However, the relationship between FOXC2 and the progression of human gliomas remains to be clarified. The aim of present study was to assess FOXC2 expression and to explore its contribution in human gliomas. Materials and Methods: Realtime quantitative PCR was performed to examine FOXC2 expression in 85 pairs of fresh frozen glioma tissues and corresponding non-neoplastic brain tissues. Associations of FOXC2 expression with clinicopathological factors and prognosis of glioma patients were statistically analyzed. Results: The relative mRNA expression of FOXC2 was significantly higher in glioma tissues than the corresponding non-neoplastic brain tissues (p<0.001). In addition, high FOXC2 expression was significantly associated with advanced pathological grade (P=0.005) and the low Karnofsky performance score (KPS) (p=0.003), correlating with poor survival (p<0.001). Furthermore, multivariate Cox regression analysis showed that high FOXC2 expression was an independent predictor of overall survival (p=0.006). Conclusions: FOXC2 may act as an oncogenic gene and represent a potential regulator of aggressive development and a candidate prognostic marker in human gliomas.
Keywords
Human glioma; forkhead box protein C2; prognosis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Bansal K, Liang ML, Rutka JT (2006). Molecular biology of human gliomas. Technol Cancer Res Treat, 5, 185-94.   DOI
2 Feng B, Hu P, Lu SJ, et al (2014). Increased argonaute 2 expression in gliomas and its association with tumor progression and poor prognosis. Asian Pac J Cancer Prev, 15, 4079-83.   DOI
3 Hollier BG, Tinnirello AA, Werden SJ, et al (2013). FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res, 73, 1981-92.   DOI
4 Jiang W, Pang XG, Wang Q, et al (2012). Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection. Clin Lung Cancer, 13, 280-7.   DOI
5 Kume T (2008). Foxc2 transcription factor: a newly described regulator of angiogenesis. Trends Cardiovasc Med, 18, 224-8.   DOI   ScienceOn
6 Kume T (2012). The role of FoxC2 transcription factor in tumor angiogenesis. J Oncol, 2012, 204593.
7 Li W, Fu X, Liu R, et al (2013). FOXC2 often overexpressed in glioblastoma enhances proliferation and invasion in glioblastoma cells. Oncol Res, 21, 111-20.
8 Liu B, Han SM, Tang XY, et al (2014). Overexpressed FOXC2 in ovarian cancer enhances the epithelial-to-mesenchymal transition and invasion of ovarian cancer cells. Oncol Rep, 31, 2545-54.
9 Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109.   DOI
10 Mani SA, Yang J, Brooks M, et al (2007). Mesenchyme forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA, 104, 10069-74.   DOI   ScienceOn
11 Meyer MA (2008). Malignant gliomas in adults. N Engl J Med, 359, 1850.
12 Nishida N, Mimori K, Yokobori T, et al (2011). FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma. Ann Surg Oncol, 18, 535-42.   DOI
13 Reni M, Mazza E, Tosoni A, et al (2005). Novel therapeutics in adult malignant brain gliomas. Expert Opin Investig Drugs, 14, 643-58.   DOI
14 Van Meir EG, Hadjipanayis CG, Norden AD, et al (2010). Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin, 60, 166-93.   DOI
15 Watanabe T, Kobunai T, Yamamoto Y, et al (2011). Gene expression of mesenchyme forkhead 1 (FOXC2) significantly correlates with the degree of lymph node metastasis in colorectal cancer. Int Surg, 96, 207-16.   DOI
16 Wu X, Liu NF (2011). FOXC2 transcription factor: a novel regulator of lymphangiogenesis. Lymphology, 44, 35-41.
17 Zheng CH, Quan Y, Li YY, et al (2014). Expression of transcription factor FOXC2 in cervical cancer and effects of silencing on cervical cancer cell proliferation. Asian Pac J Cancer Prev, 15, 1589-95.   DOI
18 Zhu JL, Song YX, Wang ZN, et al (2013). The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma. Histopathology, 62, 1038-48.   DOI